Structural mechanism of TRPC3 inhibition by a potent antagonist
Journal of Biological Chemistry · 2026-12 · 302 (12) · 113644
DOI: 10.1016/j.jbc.2026.113644 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026-12. Verfasst von Jodie Collingridge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; Kavli Institute for Nanoscience Discovery, University of…. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Environment Research Council, Biotechnology and Biological Sciences Research Council, Wellcome.
Abstract (Originalsprache)
The transient receptor channel canonical family member 3 (TRPC3) is a nonselective, calcium-permeable cation channel within the larger TRP superfamily. TRPC3 is expressed in both excitable and nonexcitable cells, where it integrates multiple signaling pathways and is directly activated by binding of diacylglycerol following activation of G-protein coupled receptors. Increased TRPC3 signaling is implicated in several diseases, highlighting TRPC3 as a potential therapeutic target. However, the development of TRPC3 inhibitors with suitable potency and selectivity has been challenging due to the channel's high structural and sequence homology with related family members, specifically TRPC6. Here, we present a highly potent TRPC3 antagonist (GSK2820986A) featuring an anilino-thiazole pharmacophore. Through a combination of molecular dynamic simulations and functional assays, we identify a putative binding site for GSK2820986A in the TRPC3 S4-S5 pocket and propose a potential inhibitory mechanism. Our findings provide a powerful tool compound and mechanistic framework to advance the investigation and therapeutic targeting of TRPC3.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom; Structural Bioinformatics and Computa…
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom.
- GSK, Medicines Research Centre, Stevenage, United Kingdom.
- Structural Bioinformatics and Computational Biochemistry, Department of Biochemistry, University of Oxford, Oxford, United Kingdom. Electronic address: philip.biggin@bioch.ox.ac.uk.
- Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, United Kingdom. Electronic address: esther.becker@ndc…
Förderung
- Natural Environment Research Council
- Biotechnology and Biological Sciences Research Council
- Wellcome
Zitieren
APA
Collingridge, J., Cole, B. A., Rowlett, M. A., Liddle, J., Gatfield, K. M., Biggin, P. C., & Becker, E. B. E. (2026). Structural mechanism of TRPC3 inhibition by a potent antagonist. Journal of Biological Chemistry, 302(12), 113644. https://doi.org/10.1016/j.jbc.2026.113644
Vancouver
Collingridge J, Cole BA, Rowlett MA, Liddle J, Gatfield KM, Biggin PC, et al. Structural mechanism of TRPC3 inhibition by a potent antagonist. Journal of Biological Chemistry. 2026;302(12):113644. doi:10.1016/j.jbc.2026.113644
BibTeX
@article{Collingridge2026,
author = {Collingridge, Jodie and Cole, Bethan A and Rowlett, Molly A and Liddle, John and Gatfield, Kelly M and Biggin, Philip C and Becker, Esther B E},
title = {Structural mechanism of TRPC3 inhibition by a potent antagonist},
journal = {Journal of Biological Chemistry},
year = {2026},
volume = {302},
number = {12},
pages = {113644},
doi = {10.1016/j.jbc.2026.113644}
}
EUVIMED